Deleted in liver cancer‑1 inhibits cell growth and tumorigenicity in human pancreatic cancer

Zheng,Zhenjiang; Tan,Chunlu; Xiang,Guangming; Mai,Gang; Liu,Xubao

doi:10.3892/ol.2013.1415

Deleted in liver cancer‑1 inhibits cell growth and tumorigenicity in human pancreatic cancer

Authors:
- Zhenjiang Zheng
- Chunlu Tan
- Guangming Xiang
- Gang Mai
- Xubao Liu
View Affiliations

Affiliations: Department of General Surgery, The Third People's Hospital of Chengdu, The Second Affiliated Hospital of Chengdu, Chongqing Medical University, Chengdu, Sichuan 610031, P.R. China, Department of Hepatobiliopancreatic Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, P.R. China
Published online on: June 18, 2013 https://doi.org/10.3892/ol.2013.1415
Pages: 521-524

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Deleted in liver cancer‑1 (DLC‑1) has been isolated from primary hepatocellular carcinoma and demonstrated to be a potential tumor suppressor gene. The aim of the present study was to observe the effect of the DLC‑1 gene on pancreatic cancer cell growth and evaluate the feasibility of using the DLC‑1 gene in gene therapy for pancreatic cancer. A recombinant plasmid (pcDNA3.1/DLC‑1) was transfected into PANC‑1 cells by liposomes and then the pre‑established human PANC‑1 pancreatic carcinoma cells were injected into athymic nude mice via the tail vein. The results showed that the overexpression of DLC‑1 in the PANC‑1 cells inhibited cell proliferation in vitro, while the act of introducing DLC‑1 reduced tumorigenicity in the nude mice. The findings suggest that DLC‑1 may have an effect on the pathogenesis of pancreatic cancer. The DLC‑1 gene may be a promising target in gene therapy for pancreatic cancer.

View Figures

View References

1.	Yuan BZ, Miller MJ, Keck CL, Zimonjic DB, Thorgeirsson SS and Popescu NC: Cloning, characterization and chromosomal localization of a gene frequently deleted in human liver cancer (DLC-1) homologous to rat RhoGAP. Cancer Res. 58:2196–2199. 1998.PubMed/NCBI
2.	Ching YP, Wong CM, Chan SF, et al: Deleted in liver cancer (DLC) 2 encodes a RhoGAP protein with growth suppressor function and is underexpressed in hepatocellular carcinoma. J Biol Chem. 278:10824–10830. 2003. View Article : Google Scholar
3.	Kawai K, Kiyota M, Seike J, Deki Y and Yagisawa H: STARTGAP3/DLC3 is a GAP for RhoA and Cdc42 and is localized in focal adhesions regulating cell morphology. Biochem Biophys Res Commun. 364:783–789. 2007. View Article : Google Scholar : PubMed/NCBI
4.	Sekimata M, Kabuyama Y, Emori Y and Homma Y: Morphological changes and detachment of adherent cells induced by p122, a GTPase-activating protein for Rho. J Biol Chem. 274:17757–17762. 1999. View Article : Google Scholar : PubMed/NCBI
5.	Wong CM, Yam JW, Ching YP, et al: Rho GTPase-activating protein deleted in liver cancer suppresses cell proliferation and invasion in hepatocellular carcinoma. Cancer Res. 65:8861–8868. 2005. View Article : Google Scholar : PubMed/NCBI
6.	Yam JW, Ko FC, Chan CY, Jin DY and Ng IO: Interaction of deleted in liver cancer 1 with tensin2 in caveolae and implications in tumor suppression. Cancer Res. 66:8367–8372. 2006. View Article : Google Scholar : PubMed/NCBI
7.	Moon SY and Zheng Y: Rho GTPase activating proteins in cell regulation. Trends Cell Biol. 13:13–22. 2003. View Article : Google Scholar : PubMed/NCBI
8.	Peck J, Douglas G 4th, Wu CH and Burbelo PD: Human RhoGAP domain-containing proteins: structure, function, and evolutionary relationships. FEBS Lett. 528:27–34. 2002. View Article : Google Scholar : PubMed/NCBI
9.	Ng IO, Liang ZD, Cao L and Lee TK: DLC-1 is deleted in primary hepatocellular carcinoma and exerts inhibitory effects on the proliferation of hepatoma cell lines with deleted DLC-1. Cancer Res. 60:6581–6584. 2000.PubMed/NCBI
10.	Gatalica Z, Velagaleti G, Kuivaniemi H, et al: Gene expression profile of an adenomyoepithelioma of the breast with a reciprocal translocation involving chromosomes 8 and 16. Cancer Genet Cytogenet. 156:14–22. 2005. View Article : Google Scholar : PubMed/NCBI
11.	Zhang X, Feng J, Cheng Y, et al: Characterization of differentially expressed genes in ovarian cancer by cDNA microarrays. Int J Gynecol Cancer. 15:50–57. 2005. View Article : Google Scholar : PubMed/NCBI
12.	Kim TY, Jong HS, Song SH, et al: Transcriptional silencing of the DLC-1 tumor suppressor gene by epigenetic mechanism in gastric cancer cells. Oncogene. 22:3943–3951. 2003. View Article : Google Scholar : PubMed/NCBI
13.	Healy KD, Kim TY, Shutes AT, Bang YJ, Juliano RL and Der CJ: RhoGAP DLC-1 tumor suppression and aberrant Rho GTPase activation in lung cancer. Proc Am Assoc Cancer Res. 47:Abstract. 41252006.
14.	Guan M, Zhou X, Soulitzis N, Spandidos DA and Popescu NC: Aberrant methylation and deacetylation of deleted in liver cancer-1 gene in prostate cancer: potential clinical applications. Clin Cancer Res. 12:1412–1419. 2006. View Article : Google Scholar : PubMed/NCBI
15.	Yuan BZ, Jefferson AM, Baldwin KT, Thorgeirsson SS, Popescu NC and Reynolds SH: DLC-1 operates as a tumor suppressor gene in human non-small cell lung carcinomas. Oncogene. 23:1405–1411. 2004. View Article : Google Scholar : PubMed/NCBI
16.	Yuan BZ, Zhou X, Durkin ME, et al: DLC-1 gene inhibits human breast cancer cell growth and in vivo tumorigenicity. Oncogene. 22:445–450. 2003. View Article : Google Scholar : PubMed/NCBI
17.	Zhou X, Thorgeirsson SS and Popescu NC: Restoration of DLC-1 gene expression induces apoptosis and inhibits both cell growth and tumorigenicity in human hepatocellular carcinoma cells. Oncogene. 23:1308–1313. 2004. View Article : Google Scholar : PubMed/NCBI
18.	Jemal A, Siegel R, Ward E, Hao Y, Xu J and Thun MJ: Cancer Statistics, 2009. CA Cancer J Clin. 59:225–249. 2009. View Article : Google Scholar
19.	Neoptolemos JP, Stoken DD, Friess H, et al: A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med. 350:1200–1210. 2004. View Article : Google Scholar : PubMed/NCBI
20.	Goodison S, Yuan J, Sloan D, et al: The RhoGAP protein DLC-1 functions as a metastasis suppressor in breast cancer cells. Cancer Res. 65:6042–6053. 2005. View Article : Google Scholar : PubMed/NCBI
21.	Wong CM, Lee JM, Ching YP, Jin DY and Ng IO: Genetic and epigenetic alterations of DLC-1 gene in hepatocellular carcinoma. Cancer Res. 63:7646–7651. 2003.PubMed/NCBI
22.	Healy KD, Hodgson L, Kim TY, et al: DLC-1 suppresses non-small cell lung cancer growth and invasion by RhoGAP-dependent and independent mechanisms. Mol Carcinog. 47:326–337. 2008. View Article : Google Scholar : PubMed/NCBI
23.	Kawai K, Yamaga M, Iwamae Y, et al: A PLCδ1-binding protein, p122RhoGAP, is localized in focal adhesions. Biochem Soc Trans. 32:1107–1109. 2004.
24.	Nabel EG, Gordon D, Yang ZY, et al: Gene transfer in vivo with DNA-liposome complexes: lack of autoimmunity and gonadal localization. Hum Gene Ther. 3:649–656. 1992. View Article : Google Scholar : PubMed/NCBI
25.	Zhu N, Liggitt D, Liu Y and Debs R: Systemic gene expression after intravenous DNA delivery into adult mice. Science. 261:209–211. 1993. View Article : Google Scholar : PubMed/NCBI
26.	Chen QR, Kumar D, Stass SA and Mixson AJ: Liposomes complexed to plasmids encoding angiostatin and endostatin inhibit breast cancer in nude mice. Cancer Res. 59:3308–3312. 1999.